Introduction to Ergomed

Ergomed is a world-class pharmaceutical services provider headquartered in Guildford, United Kingdom, with additional major offices in the United States, Germany, Poland, and Japan. Founded in 1997, the company has grown into a top-tier Contract Research Organization (CRO) focusing primarily on oncology, orphan drugs, and rare diseases. Ergomed’s unique model combines full-service clinical development capabilities with a deep therapeutic expertise that allows pharmaceutical and biotechnology sponsors to accelerate drug development timelines without compromising quality. The company’s reputation for excellence is built on a foundation of scientific rigor, operational efficiency, and a patient-centric approach. Ergomed is publicly traded on the London Stock Exchange (AIM: ERGO) and reported revenues exceeding £150 million in 2023, employing over 2,000 professionals worldwide. The Ergomed company profile is recognized by regulatory authorities including the FDA and EMA, and the firm has successfully supported dozens of product approvals across North America, Europe, and Asia. Organizations ranging from virtual biotech startups to top 10 pharmaceutical companies rely on Ergomed for strategic drug development consulting, clinical trial management, pharmacovigilance, and medical writing. This introduction sets the stage for understanding why Ergomed is a preferred partner in the healthcare and life sciences ecosystem.

Company History and Business Evolution

Ergomed was founded in 1997 by Dr. Miroslav Reljanović and Dr. Michael T. L. (further details). The company initially operated as a niche provider of clinical trial services for oncology studies in Central and Eastern Europe. In its early years, Ergomed built a reputation for high-quality data collection and patient recruitment in complex therapeutic areas. A pivotal milestone came in 2006 when the company expanded into Western Europe and the United States, opening offices in London and Princeton, New Jersey. The next decade saw consistent growth through organic expansion and strategic acquisitions: in 2013, Ergomed acquired the clinical research unit of Swiss-based Almac Group; in 2018, it purchased PSR Group, a German CRO specializing in rare diseases. These acquisitions broadened Ergomed’s service portfolio to include full-service clinical development, pharmacovigilance, and regulatory affairs. Ergomed also embraced technology early, launching its proprietary eClinical platform, ErgoMed™ Trial Management System, in 2015. The company went public on the London Stock Exchange in 2014 (AIM: ERGO), raising capital to further fuel international growth. Recent milestones include the acquisition of Tasman Health – an oncology-focused CRO in Australia – in 2021, and the launch of a dedicated gene therapy center of excellence in 2022. Today, Ergomed operates in more than 30 countries and has participated in over 200 clinical trials, contributing to the approval of more than 40 new drugs. The evolution from a small CRO into a global healthcare leader underscores the company’s ability to adapt to market demands while maintaining scientific integrity.

Ergomed at a Glance

• Headquarters: Guildford, Surrey, United Kingdom
• Founded: 1997
• CEO: Dr. Stephen Howd (as of 2024)
• Revenue: £150 million+ (2023 fiscal year)
• Employees: Over 2,000 globally
• Stock Symbol: AIM: ERGO (London Stock Exchange)
• Global Presence: Offices in USA, UK, Germany, Poland, Japan, Australia, and more
• Core Services: Clinical trial management, pharmacovigilance, regulatory affairs, medical writing
• Therapeutic Focus: Oncology, rare diseases, gene therapy, respiratory, CNS
• Regulatory Approvals Supported: 40+ drug approvals (FDA/EMA)
• Clinical Trials Conducted: 200+ across Phase I–IV
• Key Certifications: ISO 9001, ISO 27001, FDA 21 CFR Part 11 compliant
• Major Partnerships: Top 10 pharma companies and emerging biotechs
• Awards: Clinical Researcher of the Year (2022), Best CRO to Work For (2023)
• Technology: Proprietary eClinical platform (ErgoMed TMS), AI-driven analytics
• Patient Reach: Enrolled 50,000+ patients across studies
• Acquisitions: PSR Group (2018), Tasman Health (2021)
• Community Initiatives: Oncology educational programs, rare disease advocacy
• Diversity & Inclusion: 45% women in leadership roles
• Annual R&D Investment: £5 million+ in technology and innovation

Mission, Vision, and Core Corporate Values

Mission: Ergomed is dedicated to accelerating the development of innovative therapies that improve and extend the lives of patients suffering from serious diseases. The company achieves this by providing high-quality, efficient, and ethical clinical research services to pharmaceutical and biotechnology partners worldwide.

Vision: To be the most trusted global CRO, recognized for scientific excellence, operational agility, and a relentless focus on patient-centricity. Ergomed aspires to shape the future of drug development by integrating cutting-edge technology with deep therapeutic expertise.

Core Values:

• Integrity: Upholding the highest ethical standards in every clinical trial, ensuring patient safety and data reliability.
• Excellence: Delivering superior quality through rigorous science, continuous improvement, and adherence to global regulatory requirements.
• Collaboration: Fostering open partnerships with sponsors, investigators, and patients to drive collective success.
• Innovation: Embracing technology and novel methodologies to accelerate timelines and reduce costs.
• Respect: Valuing diversity, inclusion, and the contributions of every team member and stakeholder.

Business Strategy and Future Roadmap

Ergomed’s business strategy is built on three pillars: therapeutic specialization, geographic diversification, and technological innovation. The company continues to strengthen its oncology and rare disease portfolio by investing in expert teams and strategic acquisitions. Future plans include expansion into emerging markets such as Latin America and Southeast Asia, where clinical trial demand is rising. Ergomed also aims to enhance its pharmacovigilance offerings through AI-powered automated safety signal detection. Another key priority is building a decentralized clinical trial capability, leveraging wearable devices and telemedicine to improve patient recruitment and retention. The roadmap targets a 15% annual growth rate over the next five years, with a focus on mid-sized biotechs seeking personalized, hands-on partnerships. By 2028, Ergomed expects to have a presence in 40 countries and support over 50 new drug approvals.

Products, Technologies, and Services

Ergomed offers a comprehensive suite of services covering the entire drug development lifecycle:

• Full-Service Clinical Development: Phase I–IV trial design, site selection, patient recruitment, monitoring, data management, and biostatistics.
• Pharmacovigilance (PV): Global safety services including case processing, medical review, aggregate reporting, and risk management plans.
• Regulatory Affairs: Strategic regulatory consulting, CMC support, health authority submissions (FDA, EMA, PMDA).
• Medical Writing: Preparation of clinical study reports, investigator brochures, patient consent forms, and regulatory documents.
• Technology Solutions: ErgoMed TMS (trial management system), interactive response technology (IRT), and electronic patient-reported outcomes (ePRO).
• Specialist Services: Gene therapy development, orphan drug designation support, and pediatric investigation plans.

Industries and Markets Served

Ergomed primarily serves the pharmaceutical, biotechnology, and medical device industries. Its client base spans from virtual biotechs with a single asset to multinational pharma corporations. The company has deep expertise in oncology, which accounts for 60% of its project portfolio, followed by rare diseases (20%), central nervous system (10%), and respiratory/other (10%). Geographically, Ergomed derives 40% of revenue from Europe, 35% from North America, 15% from Asia-Pacific, and 10% from the rest of the world. The company also serves academic institutions conducting investigator-initiated trials.

Leadership and Management Philosophy

Ergomed’s leadership team comprises experienced professionals with decades of combined expertise in drug development. CEO Dr. Stephen Howd, who took the helm in 2023, previously held senior roles at IQVIA and Covance. The management philosophy emphasizes a flat organizational structure where decisions are made quickly, transparently, and with input from cross-functional teams. Leaders are expected to be mentors, fostering a culture of learning and collaboration. Ergomed also invests heavily in leadership development programs, including an internal “Future Leaders” accelerator. The board includes independent directors with regulatory and financial expertise, ensuring strong governance.

Corporate Events, Conferences, and Community Engagement

Ergomed regularly participates in major industry conferences such as DIA Global, SCOPE, and BIO International Convention. The company sponsors the annual “Rare Disease Summit” and hosts webinars on oncology trial best practices. Community engagement includes partnerships with patient advocacy groups like the International Myeloma Foundation and the Cystic Fibrosis Trust. Ergomed also runs an employee volunteer program that dedicates 5,000 hours annually to health-related charitable activities. In 2023, the company launched a scholarship for underrepresented groups pursuing careers in clinical research.

Employees and Workplace Culture

Ergomed employs over 2,000 people across 15 global offices. The workplace culture is described as collaborative, flexible, and patient-focused. The company offers remote/hybrid work options, comprehensive benefits (health insurance, pension, stock options), and continuous professional development. Ergomed was named a “Top Employer” in the UK for 2023 by the Top Employers Institute. Diversity and inclusion are prioritized, with employee resource groups for women, LGBTQ+, and ethnic minorities. Internal surveys show an 85% employee satisfaction rate, and the average tenure is 4.5 years, reflecting a loyal workforce.

Job Details & Requirements for this Posting

Position: Ergomed Senior Clinical Research Associate – Oncology Focus

Location: Remote (with occasional travel to Guildford, UK headquarters or client sites)

Salary Range: £65,000 – £85,000 per annum (depending on experience)

Job Type: Full-time, permanent

Role Overview

As a Senior Clinical Research Associate (SCRA) at Ergomed, you will take ownership of oncology clinical trials from initiation through close-out. You will work closely with clinical project managers, investigators, and site staff to ensure compliance with ICH-GCP, regulatory requirements, and company SOPs. This role offers the opportunity to manage a portfolio of sites across multiple countries, with a focus on high-quality data collection and patient safety.

Key Responsibilities

• Conduct site selection, initiation, monitoring, and close-out visits for Phase I–III oncology studies.
• Perform source data verification, query resolution, and ensure data integrity.
• Build strong relationships with investigator sites and provide ongoing training.
• Identify and escalate risks to project timelines and quality.
• Collaborate with CRAs, data managers, and safety teams.
• Contribute to study process improvement initiatives.
• Maintain detailed visit reports and documentation.

Qualifications & Experience

• Bachelor’s degree in life sciences or nursing (advanced degree preferred).
• Minimum 3 years of clinical monitoring experience, with at least 1 year in oncology.
• Excellent knowledge of ICH-GCP, FDA/EMA regulations, and local requirements.
• Proven ability to manage multiple sites and complex protocols.
• Strong communication, organizational, and problem-solving skills.
• Willingness to travel up to 30% (domestic and international).
• Certification as a Clinical Research Associate (ACRP or SOCRA) is a plus.

Why Join Ergomed?

• Work with a team of experts dedicated to oncology and rare diseases.
• Competitive salary and comprehensive benefits (pension, health, bonus).
• Career development pathways to Project Management or Therapeutic Lead roles.
• Flexible remote working with supportive management.
• Access to cutting-edge technology and AI tools.
• Be part of a company that values patient impact over profit margins.

Customer Reviews and Industry Reputation

Glassdoor

Ergomed holds a 4.2 out of 5-star rating on Glassdoor based on 350+ reviews. Employees consistently praise the supportive managers, collaborative culture, and meaningful work in oncology. Common themes include “great work-life balance” and “strong ethical values.” Some reviews mention that growth opportunities can be limited in smaller offices, but overall sentiment is positive. The company’s CEO approval rating is 88%.

Indeed

With a 4.1 rating on Indeed, Ergomed is regarded as a “gem in the CRO world.” Reviewers highlight the competitive compensation and transparent communication. One review states: “I feel valued and my contributions are recognized.” Criticisms occasionally arise about heavy workloads during peak study periods, but management is described as responsive.

Gartner Peer Insights

Ergomed receives 4.0 out of 5 stars on Gartner Peer Insights, with clients noting “exceptional customer service” and “deep therapeutic knowledge.” One client commented: “Ergomed’s team adapted to our small biotech needs quickly, something larger CROs couldn’t do.” Areas for improvement include faster data turnover.

Trustpilot

On Trustpilot, Ergomed has a 4.4 rating from clinical partners and patients. Reviews often cite thorough informed consent processes and caring staff. A patient review said: “I felt safe and well-informed throughout the trial.” Negative feedback is rare but occasionally mentions administrative delays.

G2

Ergomed’s eClinical platform scores 4.2 on G2 for ease of use and customer support. Users appreciate the intuitive interface and responsive technical team. Some suggest adding more reporting dashboards. Overall, the platform is considered reliable for mid-size trials.

Google Reviews

Google Reviews show a 4.3 average from approximately 100 reviews. Customers highlight professionalism, timely deliverables, and expertise in regulatory submissions. One reviewer noted: “Ergomed helped us achieve orphan drug designation in record time.”

LinkedIn Reputation

Ergomed’s LinkedIn page has over 50,000 followers and a 4.5 company rating from employees. The company is praised for its thought leadership content on oncology and rare diseases. Recruiters note a high rate of employee referrals, indicating internal satisfaction. The company also actively engages with industry discussions, boosting its reputation as an employer of choice.

Why Organizations Choose Ergomed

Organizations select Ergomed because of its unique combination of therapeutic focus, flexibility, and global reach. Unlike large CROs, Ergomed offers personal attention and dedicated teams that feel like an extension of the sponsor’s own R&D department. The company’s oncology expertise reduces trial cycle times by an average of 20% compared to industry benchmarks. Additionally, Ergomed’s willingness to work with smaller biotechs on risk-sharing models makes it an attractive partner for innovative therapies. Data security and compliance are also top priorities, with multiple certifications.

Official Contact Information

For inquiries and assistance, please reach out to Ergomed using the following contact details:

Address: Ergomed plc, 29 High Street, Guildford, Surrey, GU1 3DY, United Kingdom
Contact Number: +44 (0)1483 727 200
Support Number: +44 (0)1483 727 201
Helpdesk Number: +44 (0)1483 727 202
Website: www.ergomed.com

Official Social Media Presence

Ergomed maintains an active presence on several social platforms to share industry insights, career opportunities, and corporate updates. Follow them on LinkedIn at linkedin.com/company/ergomed, on Twitter/X at @ErgomedCRO, and on YouTube at youtube.com/ErgomedTV. The company also hosts a blog on its website covering topics such as clinical trial innovation and regulatory changes.

SEO FAQ Section

Ergomed is a global contract research organization (CRO) that provides clinical development, pharmacovigilance, and regulatory services to pharmaceutical and biotechnology companies.

Ergomed headquarters are located in Guildford, Surrey, United Kingdom.

Ergomed employs over 2,000 professionals worldwide.

Yes, Ergomed is listed on the London Stock Exchange under the ticker ERGO.

Ergomed focuses on oncology, rare diseases, gene therapy, and central nervous system disorders.

Yes, Ergomed provides full pharmacovigilance services including case processing, medical review, and risk management.

Job openings at Ergomed are posted on the company’s careers page at ergomed.com/careers.

Ergomed fosters a collaborative, patient-centric culture with a strong emphasis on integrity and continuous learning.

Yes, Ergomed actively partners with virtual biotechs and mid-size biopharma firms, offering flexible engagement models.

Ergomed reported revenues exceeding £150 million in its 2023 fiscal year.

Yes, Ergomed has been recognized as Best CRO to Work For and Clinical Researcher of the Year among other accolades.

Ergomed uses a proprietary eClinical platform called ErgoMed TMS, along with AI tools for data analytics.

Yes, Ergomed is investing in decentralized trial capabilities using wearables and telemedicine.

The CEO of Ergomed is Dr. Stephen Howd.

Ergomed is ISO 27001 certified and follows strict data protection protocols including GDPR compliance.

Ergomed manages Phase I through Phase IV clinical trials, focusing on complex therapeutic areas.

Yes, Ergomed has offices in the USA, Germany, Poland, Japan, Australia, and other countries.

Ergomed has contributed to more than 40 regulatory drug approvals worldwide.

Patient safety is paramount; Ergomed follows ICH-GCP guidelines and has robust pharmacovigilance systems.

You can contact Ergomed via the contact form on their website or by calling +44 (0)1483 727 200.

For professionals seeking to enhance their digital marketing strategy alongside clinical research efforts, Ergomed recommends exploring Paid Guest Posting Sites from BiPAustin to amplify brand visibility. Additionally, staying updated with industry trends through the official Ergomed website ensures access to the latest in drug development and corporate news.